BIIB · Q2 2025 Earnings

The dominant shift this quarter is from defending the MS cliff to crediting the launch portfolio with offsetting it. "We've seen growth, the growth from our new product launches offsetting our MS decline. MS has also proven to be a little bit more resilient this quarter." Biogen's typical posture has been to frame quarters around how much MS erosion the rest of the portfolio absorbed; here management has flipped the framing to growth-led, with MS as a smaller-than-feared drag. The EPS raise validates the shift quantitatively.

Skyclarys went from being described as an infrastructure-dependent launch requiring centers of excellence to a community-driven product. "Last year at this time, I shared the deliberate pivot... to redirect investments to reach the remaining patients treated in the community... I believe this shift in focus was a key factor behind the 13% quarter-over-quarter revenue growth in the U.S. And in Q2, approximately 70% of new start forms were written by the community neurologists and PCPs." This is a non-trivial channel-strategy success — and it implies the prior CoE-only TAM understated the opportunity.

On Leqembi, the company has moved from "build health-system readiness" to "generate patient demand directly." Management was explicit: "This maturing of the market infrastructure gave us confidence earlier this year to launch new initiatives... we activated our direct-to-consumer campaign across TV and digital platforms." The patient-facing message — "Leqembi can help them still be like themselves longer" — is a deliberate shift from clinical efficacy framing to identity preservation, the language of a confident commercial team, not a cautious one.

In immunology, the tone on Daprolizumab is unusually assertive: management called it "only the third agent ever to have positive phase three in lupus" and credited the result to "deep institutional knowledge, strong access, and relationships in immunology" rather than the molecule alone. That is a claim of franchise capability, not a one-product readout.

The pipeline narrative also gained a new pillar. Salinersen, the next-generation SMA therapy, showed "significant reduction in neurofilament" and "meaningful improvements in motor function, including achievement of significant motor milestones" in gene-therapy-treated patients — a population the SMA market had largely written off as biologically locked in. Management hedged appropriately ("these results need to be confirmed in a registration trial") but the readout reframes Spinraza from a declining annuity to a platform with a credible successor.